How should a dual‑energy X‑ray absorptiometry (DEXA) scan be interpreted and when is zoledronic acid indicated?

How to Interpret DEXA and When to Give Zoledronic Acid

Perform DEXA at the lumbar spine, total hip, and femoral neck; diagnose osteoporosis when T-score ≤ -2.5 at any site, and initiate zoledronic acid for malignancy-related bone disease (hypercalcemia of malignancy, multiple myeloma, or bone metastases from solid tumors) but NOT for primary osteoporosis management. 1, 2

DEXA Interpretation

Who Should Get DEXA Screening

Based on the most recent 2025 guidelines, obtain DEXA in:

• All women ≥65 years 1
• All men >70 years 1
• Women and men ≥50 years with risk factors including:
  • Low body weight
  • Parental hip fracture history
  • Smoking
  • Excess alcohol use
  • Glucocorticoid therapy (≥5 mg prednisone equivalent daily for ≥3 months)
  • Conditions causing bone loss (hyperparathyroidism, rheumatoid arthritis)
  • Previous fragility fracture 3, 1

For postmenopausal women <65 years, use a two-step approach: first identify risk factors, then apply a clinical risk assessment tool (FRAX, FRC, or Garvan) to determine if screening is warranted 3.

Reading the DEXA Report

Measurement sites: The scan must assess lumbar spine, femoral neck, and total hip. Add one-third radius if indicated 1.

T-score interpretation (number of standard deviations from young healthy reference):

• Normal: T-score ≥ -1.0
• Osteopenia: T-score between -1.0 and -2.5
• Osteoporosis: T-score ≤ -2.5 at any measured site 1

Use the lowest T-score from any site for diagnosis 1. The WHO operational definition is based on femoral neck measurements, but all sites are interpreted analogously in clinical practice 1.

Critical caveat: T-scores alone underestimate fracture risk, especially in younger populations 3. BMD correlates with bone strength but doesn't capture bone quality deterioration or fall risk that increases with age 3. A 70-year-old and 50-year-old with identical BMD have vastly different fracture risks.

Artifacts and Technical Issues to Recognize

Reject or reinterpret scans with:

• Degenerative changes, aortic calcification, or vertebral compression fractures at lumbar spine
• Hip prostheses, gluteal implants, or incorrect femur rotation
• Paget's disease or bone metastases
• Incorrect region-of-interest positioning 1

DXA limitation: Two-dimensional projection underestimates volumetric density in short patients and overestimates in tall patients 1.

Serial Monitoring

Timing: Repeat DEXA every 1-5 years depending on clinical circumstances and treatment status 1. Use the same facility and machine when possible 1.

Least Significant Change (LSC): Each facility must calculate its precision error and LSC. Only BMD changes exceeding the LSC represent true biological change rather than measurement variability 1, 4. Without knowing your facility's LSC, you cannot interpret serial measurements 4.

Vertebral Fracture Assessment (VFA)

Perform VFA or standard radiography in patients ≥50 years with:

• T-score < -1.0 AND (women ≥70 years OR men ≥80 years)
• Historical height loss >4 cm
• Self-reported undocumented vertebral fracture
• Long-term glucocorticoid therapy 1

When to Give Zoledronic Acid

Critical distinction: The FDA-approved zoledronic acid formulation discussed in the provided evidence is indicated ONLY for malignancy-related conditions, NOT primary osteoporosis 2.

FDA-Approved Indications for Zoledronic Acid

Give zoledronic acid 4 mg IV for:

1. Hypercalcemia of malignancy: Single 4 mg infusion over ≥15 minutes; may retreat after minimum 7 days 2

2. Multiple myeloma with bone involvement: 4 mg IV every 3-4 weeks over ≥15 minutes 2

3. Documented bone metastases from solid tumors (in conjunction with standard antineoplastic therapy):

   • Breast cancer
   • Prostate cancer (must have progressed after ≥1 hormonal therapy)
   • Other solid tumors 2

Dosing Adjustments and Monitoring

Renal function requirements:

• Standard 4 mg dose: CrCl >60 mL/min
• Reduce dose for CrCl 30-60 mL/min
• Do NOT use in severe renal impairment (CrCl <30 mL/min) 2
• Monitor serum creatinine before each dose 2

Recent evidence suggests reduced doses (≤3 mg) may be safe in advanced CKD patients (CrCl <35 mL/min) with hip fractures, though this is off-label 5.

Mandatory co-administration:

• Oral calcium 500 mg daily
• Vitamin D 400 IU daily 2

Pre-treatment requirements:

• Adequately rehydrate patients with hypercalcemia of malignancy 2
• Correct pre-existing hypocalcemia before initiating therapy 2
• Monitor electrolytes during treatment 2

Critical Safety Warnings

Osteonecrosis of the jaw (ONJ): Perform preventive dental examination before starting; avoid invasive dental procedures during treatment 2.

Atypical femoral fractures: Evaluate any patient with thigh or groin pain to rule out atypical subtrochanteric/diaphyseal fracture. Consider discontinuation if suspected 2.

Severe bone/joint/muscle pain: May be incapacitating; discontinue if severe symptoms occur 2.

Pregnancy: Can cause fetal harm; females of reproductive potential must use effective contraception 2.

Administration Details

• Infuse through separate vented line over ≥15 minutes
• Do NOT mix with calcium or divalent cation-containing solutions
• Dilute 4 mg/5 mL vial before infusion 2

Important limitation: The safety and efficacy of zoledronic acid has NOT been established for hyperparathyroidism or non-tumor-related hypercalcemia 2.